Stimcell Energetics (STME) Asset Writedowns and Impairment (2017 - 2025)
Stimcell Energetics' (STME) quarterly Asset Writedowns and Impairment came in at $130000.0 in Q4 2025, up 8.33% quarter-over-quarter from $120000.0 in Q3 2025.
Stimcell Energetics (STME) Asset Writedowns and Impairment (2017 - 2025) Analysis & Trends
Stimcell Energetics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $130000.0 for Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $130000.0 in Q4 2025; TTM through Feb 2026 was $357750.0, a N/A change from a year earlier, with the FY2025 full-year figure at $107750.0, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $130000.0 in Q4 2025 per STME's latest filing, from $120000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $130000.0 in Q4 2025 and bottomed at $107750.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn |
| 2 | Stryker | 128.82 Bn | 125.94 Bn | 3.81 Bn |
| 3 | Medtronic | 108.74 Bn | 99.52 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.40 Bn | 66.95 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.42 Bn | 43.74 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.47 Bn | 26.18 Bn | 1.98 Bn |
| 7 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.39 Bn | 2.07 Bn |
| 10 | Stimcell Energetics | 5.85 Mn | 5.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 130,000.00 |
| Nov 30, 2025 | 130,000.00 |
| Aug 31, 2025 | 120,000.00 |
| Aug 31, 2025 | 120,000.00 |
| May 31, 2025 | 107,750.00 |
| May 31, 2025 | 107,750.00 |
| Aug 31, 2017 | 522,407.00 |
| Aug 31, 2017 | 522,407.00 |